Clinical Trial Update: Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC) with unclear status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Institute of Cancer Research, United Kingdom | Conditions: Castration-resistant Prostate Cancer | Phase 2 | Status: UNKNOWN